Divi's Laboratories Limited (DIVISLAB) — Board Meeting | 3 February 2025(2 announcements)
Divi's Laboratories reported a 25.7% YoY jump in consolidated total income to ₹2401 crores for Q3 FY25, with profit before tax rising 48.5% to ₹726 crores and profit after tax up 64.4% to ₹589 crores. The board approved unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2024, and reappointed Dr. Kiran S. Divi as Whole-time Director and CEO for five years effective April 1, 2025, subject to shareholder approval. The company highlighted new commercial operations at its Kakinada project and tax benefit elections under Section 115BAA.
Divi's Laboratories announced on February 3, 2025, that Manoranjan Jasti and Suresh Ravi were designated as Senior Management Personnel effective immediately, following board approval of their appointment terms. The filing confirms their current roles — Jasti as Chief Information Officer and Ravi as Deputy General Manager (Engineering) — and outlines their expanded responsibilities in IT strategy and manufacturing operations. This structural reinforcement aims to strengthen operational continuity and leadership depth within the company.
About Divi's Laboratories Limited (DIVISLAB)
Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE
📡 Get AI alerts when DIVISLAB files next
Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions
Track DIVISLAB — Free💡 Ask AI about this filing
📊 More DIVISLAB filings
- 🟡 Board Meeting — 10 August 2026 Divi's Laboratories held its 36th AGM on August 10, 2026, via video conferencing, where shareholders...
- 🔴 Financial Results — 6 August 2026 Divi's Laboratories reported consolidated revenue of ₹3,144 crores and profit after tax of ₹902 cror...
- Announcement — 1 August 2026 Divi's Laboratories announced that the audio recording of its Q1 FY27 earnings conference call held ...
- Announcement — 1 August 2026 Divi's Laboratories announced its August 1, 2026 board meeting outcomes, approving unaudited standal...
- 🟡 Board Meeting — 1 August 2026 Divi's Laboratories reported unaudited standalone financial results for Q1 FY2026 ending June 30, 20...
🔥 Also filed on 3 February 2025
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when DIVISLAB files new disclosures
Track DIVISLAB filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track DIVISLAB — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research